00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
23:07 , May 14, 2019 |  BC Extra  |  Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
23:53 , Mar 14, 2019 |  BC Week In Review  |  Company News

FDA pushes back PDUFA for Bavarian's smallpox vaccine

Bavarian Nordic said FDA extended by three months its review of a BLA for its smallpox vaccine, MVA-BN. The new PDUFA date is in September. Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY) said the agency needs more...
22:52 , Oct 26, 2018 |  BC Extra  |  Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

Immunology and oncology company Principia Biopharma Inc. (NASDAQ:PRNB) hired Dolca Thomas as CMO. She succeeds Steve Gourlay, who will remain as a senior medical adviser through mid-2019. Thomas was VP and global head of translational...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
22:29 , May 31, 2018 |  BC Extra  |  Company News

Management tracks: Axcella, Arcturus, Orexo

Metabolic dysregulation company Axcella Health Inc. (Cambridge, Mass.) hired William Hinshaw as president and CEO. He was EVP and head of U.S. oncology at Novartis AG (NYSE:NVS; SIX:NOVN). RNA therapeutics company Arcturus Therapeutics Ltd. (NASDAQ:ARCT)...
18:52 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Rat studies suggest vaccination during pregnancy with a vaccine based on RSV F and G proteins could help prevent RSV infection in offspring. The vaccine consists of Newcastle disease virus-like...
15:31 , May 25, 2018 |  BC Week In Review  |  Clinical News

Bavarian Nordic's ProstVac misses OS endpoint in Phase III for CRPC

Bavarian Nordic A/S (CSE:BAVA) said ProstVac rilimogene galvacirepvec alone and in combination with GM-CSF both missed the primary endpoint of improving overall survival (OS) vs. placebo in the Phase III PROSPECT trial to treat metastatic...